Compare SKYX & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYX | PEPG |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.5M | 179.4M |
| IPO Year | 2014 | 2022 |
| Metric | SKYX | PEPG |
|---|---|---|
| Price | $1.18 | $2.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $4.00 | ★ $10.19 |
| AVG Volume (30 Days) | 718.3K | ★ 792.8K |
| Earning Date | 11-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.11 | ★ 25.61 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,700,948.00 | N/A |
| Revenue This Year | $16.10 | N/A |
| Revenue Next Year | $27.95 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.78 | N/A |
| 52 Week Low | $0.95 | $1.31 |
| 52 Week High | $3.29 | $7.80 |
| Indicator | SKYX | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 45.31 | 36.72 |
| Support Level | $1.15 | $1.60 |
| Resistance Level | $1.20 | $2.62 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 27.27 | 15.85 |
SKYX Platforms Corp operates in the business of developing proprietary technology that enables a quick and safe installation of electrical fixtures, such as light fixtures and ceiling fans. Its technology consists of a weight-bearing, fixable socket and a revolving plug for conducting electric power and supporting an electrical appliance attached to a wall or ceiling. The socket is comprised of a nonconductive body that houses conductive rings connectable to an electric power supply through terminals in its side exterior. The plug is also comprised of a nonconductive body that houses corresponding conductive rings, attaches to the socket via a male post, and is capable of feeding electric power to an appliance. It generates its income from lighting and heating products sold in the USA.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.